Skip to content

Clinical research on laparoscopic surgery for ovarian, fallopian tubal, and peritoneal cancer

Clinical research on laparoscopic surgery for ovarian, fallopian tubal, and peritoneal cancer - LAP-OVC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000053566
Enrollment
450
Registered
2024-02-08
Start date
2023-09-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer, tubal cancer, peritoneal cancer

Interventions

Open surgery for ovarian cancer (standard treatment) Laparoscopic surgery for ovarian cancer

Sponsors

Oita University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Early ovarian cancer that can be removed without tumor failure (including tubal cancer and borderline malignant ovarian tumors) 2)Advanced stage ovarian cancer (Also includes borderline malignant ovarian tumors, including fallopian tube and peritoneal cancers) treated preoperatively and considered resectable 3)Patients with an ECOG Performance Status of 0 ~ 2 4)Patients with adequate major organ function (laboratory tests should be done within 28 days before surgery) Neutrophil count 1,000/mm3 or greater, platelet count 100,000/mm3 or greater, AST, ALT 100 IU/L or less, serum total bilirubin < 1.5 mg/dl, serum creatinine < 1.5 mg/dl, normal ECG range or no symptoms and no need for treatment (Cases without heart disease or serious arrhythmias) 5)Patients aged 18 years or older at enrollment (upper limit not specified) 6)Patients who provided written consent to participate in the study

Exclusion criteria

Exclusion criteria: 1)Patients who do not meet the inclusion criteria 2)Patients with serious complications Example: Exclude patients with serious cardiac or cerebrovascular disease, difficult-to-control diabetes or hypertension with HbA1c > 8.5%, pulmonary fibrosis, interstitial pneumonia, bleeding, active peptic ulcer disease, or serious neurological disease. 3)Patients who are expected to have difficulty completing or following up with the study or who are deemed unsuitable by their physician

Design outcomes

Primary

MeasureTime frame
Occurrence of intestinal obstruction within 30 days of surgery

Secondary

MeasureTime frame
Perioperative complications (other than bowel obstruction) within 30 days of surgery, recurrence-free survival, and overall survival

Countries

Japan

Contacts

Public ContactMasakazu Nishida

Oita University Obstetrics and Gynecology

nishida@oita-u.ac.jp097-586-5922

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026